STAT3 and T-cell non-Hodgkin lymphoma: Using cytokine array analyses, we found that IL-6 was increased in PI3K inhibitor-resistant B- and T-cell lymphoma cells, and showed that the acquired resistance to copanlisib and duvelisib reflected two mechanisms in common: upregulation of IL-6 and activation of STAT3/5.